NEW YORK (GenomeWeb News) – KineMed today announced the renewal of its non-exclusive research collaboration with Pfizer.

The deal was originally forged a year ago and seeks to develop new approaches to specific metabolic diseases, in particular type 2 diabetes. Under the agreement, KineMed's dynamic proteomics technology platform will be used to map the impact of potential drug candidates, the Emeryville, Calif.-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

Mar
05
Sponsored by
SomaLogic

In this live webcast, Robert Gerszten of Massachusetts General Hospital will describe an ongoing project that is integrating metabolic and proteomic profiling to gain a better understanding of cardiometabolic disease.